{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:03:07Z","timestamp":1789398187665,"version":"build-2803163510"},"reference-count":285,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"the China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2024M753586"],"award-info":[{"award-number":["2024M753586"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Central Public-interest Scientific Institution Basal Research Fund","award":["2026JB09"],"award-info":[{"award-number":["2026JB09"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32473001"],"award-info":[{"award-number":["32473001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National Key Research and Development Program of China","award":["2023YFD1800700"],"award-info":[{"award-number":["2023YFD1800700"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04703-9","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:25:09Z","timestamp":1782408309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Virus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health"],"prefix":"10.1186","volume":"24","author":[{"given":"Yingqi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangli","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"4703_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02305-x","volume":"24","author":"M Zhang","year":"2025","unstructured":"Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh M, Nabavi N, et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer. 2025;24:136.","journal-title":"Mol Cancer"},{"key":"4703_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduction and Targeted Therapy. 2024;9:175.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"4703_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81\u201394.","journal-title":"Nat Rev Clin Oncol"},{"key":"4703_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw8412","author":"A Lin","year":"2019","unstructured":"Lin A, Giuliano CJ, Palladino A, John KM, Abramowicz C, Yuan ML, et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aaw8412.","journal-title":"Sci Transl Med"},{"key":"4703_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36:471\u201382.","journal-title":"Cancer Cell"},{"key":"4703_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"4703_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","volume":"19","author":"S Nooraei","year":"2021","unstructured":"Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ, Ahmadian G. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnol. 2021;19:59.","journal-title":"J Nanobiotechnol"},{"key":"4703_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/v12050488","author":"JC Caldeira","year":"2020","unstructured":"Caldeira JC, Perrine M, Pericle F, Cavallo F. Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines. Viruses. 2020. https:\/\/doi.org\/10.3390\/v12050488.","journal-title":"Viruses"},{"key":"4703_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0587-z","volume":"7","author":"MO Mohsen","year":"2019","unstructured":"Mohsen MO, Heath MD, Cabral-Miranda G, Lipp C, Zeltins A, Sande M, et al. Vaccination with nanoparticles combined with micro-adjuvants protects against cancer. Journal for ImmunoTherapy of Cancer. 2019;7:114.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"4703_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12951-023-01977-1","volume":"21","author":"Y Li","year":"2023","unstructured":"Li Y, Li S, Jiang Z, Tan K, Meng Y, Zhang D, Ma X. Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions. J Nanobiotechnol. 2023;21:212.","journal-title":"J Nanobiotechnol"},{"key":"4703_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41541-021-00330-7","volume":"6","author":"B Nguyen","year":"2021","unstructured":"Nguyen B, Tolia NH. Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines. 2021;6:70.","journal-title":"NPJ Vaccines"},{"key":"4703_CR12","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3389\/fimmu.2020.01100","volume":"11","author":"J Zepeda-Cervantes","year":"2020","unstructured":"Zepeda-Cervantes J, Ramirez-Jarquin JO, Vaca L. Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs. Front Immunol. 2020;11:1100.","journal-title":"Front Immunol"},{"key":"4703_CR13","doi-asserted-by":"publisher","first-page":"e1907150","DOI":"10.1002\/smll.201907150","volume":"16","author":"C Wang","year":"2020","unstructured":"Wang C, Fernandez de Avila BE, Mundaca-Uribe R, Lopez-Ramirez MA, Ramirez-Herrera DE, Shukla S, Steinmetz NF, Wang J. Active Delivery of VLPs Promotes Anti-Tumor Activity in a Mouse Ovarian Tumor Model. Small. 2020;16:e1907150.","journal-title":"Small"},{"key":"4703_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12967-023-04843-8","volume":"22","author":"A Barajas","year":"2024","unstructured":"Barajas A, Amengual-Rigo P, Pons-Grifols A, Ortiz R, Gracia Carmona O, Urrea V, de la Iglesia N, Blanco-Heredia J, Anjos-Souza C, Varela I, et al. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice. J Transl Med. 2024;22:14.","journal-title":"J Transl Med"},{"key":"4703_CR15","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1021\/acs.nanolett.2c00478","volume":"22","author":"H Yao","year":"2022","unstructured":"Yao H, Shen N, Ji G, Huang J, Sun J, Wang G, Tang Z, Chen X. Cisplatin Nanoparticles Promote Intratumoral CD8(+) T Cell Priming via Antigen Presentation and T Cell Receptor Crosstalk. Nano Lett. 2022;22:3328\u201339.","journal-title":"Nano Lett"},{"key":"4703_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12951-022-01357-1","volume":"20","author":"M Panasiuk","year":"2022","unstructured":"Panasiuk M, Zimmer K, Czarnota A, Narajczyk M, Peszynska-Sularz G, Chraniuk M, Hovhannisyan L, Zoledowska S, Nidzworski D, Zaczek AJ, Gromadzka B. Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy. J Nanobiotechnol. 2022;20:160.","journal-title":"J Nanobiotechnol"},{"key":"4703_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.copbio.2013.11.005","volume":"28","author":"JA Rosenthal","year":"2014","unstructured":"Rosenthal JA, Chen L, Baker JL, Putnam D, DeLisa MP. Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale. Curr Opin Biotechnol. 2014;28:51\u20138.","journal-title":"Curr Opin Biotechnol"},{"key":"4703_CR18","doi-asserted-by":"crossref","unstructured":"Vanova J, Hejtmankova A, Kalbacova MH, Spanielova H. The utilization of cell-penetrating peptides in the intracellular delivery of viral nanoparticles. Mater (Basel). 2019;12:2671.","DOI":"10.3390\/ma12172671"},{"key":"4703_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccell.2022.01.006","volume":"40","author":"MP Vincent","year":"2022","unstructured":"Vincent MP, Navidzadeh JO, Bobbala S, Scott EA. Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy. Cancer Cell. 2022;40:255\u201376.","journal-title":"Cancer Cell"},{"key":"4703_CR20","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1093\/nar\/gkw1154","volume":"45","author":"PY Fang","year":"2017","unstructured":"Fang PY, Gomez Ramos LM, Holguin SY, Hsiao C, Bowman JC, Yang HW, et al. Functional RNAs: combined assembly and packaging in VLPs. Nucleic Acids Res. 2017;45:3519\u201327.","journal-title":"Nucleic Acids Res"},{"key":"4703_CR21","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1021\/nn201397z","volume":"5","author":"CE Ashley","year":"2011","unstructured":"Ashley CE, Carnes EC, Phillips GK, Durfee PN, Buley MD, Lino CA, et al. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano. 2011;5:5729\u201345.","journal-title":"ACS Nano"},{"key":"4703_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201904958","volume":"32","author":"H Wu","year":"2020","unstructured":"Wu H, Zhong D, Zhang Z, Li Y, Zhang X, Li Y, et al. Bioinspired Artificial Tobacco Mosaic Virus with Combined Oncolytic Properties to Completely Destroy Multidrug-Resistant Cancer. Adv Mater. 2020;32:e1904958.","journal-title":"Adv Mater"},{"key":"4703_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109207","volume":"35","author":"JR Hamilton","year":"2021","unstructured":"Hamilton JR, Tsuchida CA, Nguyen DN, Shy BR, McGarrigle ER, Sandoval Espinoza CR, et al. Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering. Cell Rep. 2021;35:109207.","journal-title":"Cell Rep"},{"key":"4703_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1123805","volume":"14","author":"R Gupta","year":"2023","unstructured":"Gupta R, Arora K, Roy SS, Joseph A, Rastogi R, Arora NM, et al. Platforms, advances, and technical challenges in virus-like particles-based vaccines. Front Immunol. 2023;14:1123805.","journal-title":"Front Immunol"},{"key":"4703_CR25","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s00262-021-02897-5","volume":"70","author":"B Bareham","year":"2021","unstructured":"Bareham B, Georgakopoulos N, Matas-Cespedes A, Curran M, Saeb-Parsy K. Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies. Cancer Immunol Immunother. 2021;70:2737\u201350.","journal-title":"Cancer Immunol Immunother"},{"key":"4703_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.trecan.2023.03.009","volume":"9","author":"M Bosenberg","year":"2023","unstructured":"Bosenberg M, Liu ET, Yu CI, Palucka K. Mouse models for immuno-oncology. Trends in Cancer. 2023;9:578\u201390.","journal-title":"Trends in Cancer"},{"key":"4703_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev-cancerbio-062822-024810","volume":"9","author":"F Exposito","year":"2025","unstructured":"Exposito F, Connolly KA, Tang T, Chiorazzi M, Hunt BG, Cardenas JJ, et al. Preclinical Models of Solid Cancers for Testing Cancer Immunotherapies. Annu Rev Cancer Biol. 2025;9:285\u2013305.","journal-title":"Annu Rev Cancer Biol"},{"key":"4703_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41568-020-0297-3","volume":"20","author":"AK LeBlanc","year":"2020","unstructured":"LeBlanc AK, Mazcko CN. Improving human cancer therapy through the evaluation of pet dogs. Nat Rev Cancer. 2020;20:727\u201342.","journal-title":"Nat Rev Cancer"},{"key":"4703_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/biology11010054","author":"A Giuliano","year":"2021","unstructured":"Giuliano A. Companion Animal Model in Translational Oncology; Feline Oral Squamous Cell Carcinoma and Canine Oral Melanoma. Biology (Basel). 2021. https:\/\/doi.org\/10.3390\/biology11010054.","journal-title":"Biology (Basel)"},{"key":"4703_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10090330","author":"J Wang","year":"2018","unstructured":"Wang J, Wang T, Sun Y, Feng Y, Kisseberth WC, Henry CJ, et al. Proliferative and Invasive Colorectal Tumors in Pet Dogs Provide Unique Insights into Human Colorectal Cancer. Cancers (Basel). 2018. https:\/\/doi.org\/10.3390\/cancers10090330.","journal-title":"Cancers (Basel)"},{"key":"4703_CR31","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1158\/1078-0432.CCR-24-1854","volume":"30","author":"S Patkar","year":"2024","unstructured":"Patkar S, Mannheimer J, Harmon SA, Ramirez CJ, Mazcko CN, Choyke PL, Brown GT, Turkbey B, LeBlanc AK, Beck JA. Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes. Clin Cancer Res. 2024;30:5630\u201342.","journal-title":"Clin Cancer Res"},{"key":"4703_CR32","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1158\/1078-0432.CCR-23-2266","volume":"30","author":"JN Bryan","year":"2024","unstructured":"Bryan JN, Maitz CA. Translational History and Hope of Immunotherapy of Canine Tumors. Clin Cancer Res. 2024;30:4272\u201385.","journal-title":"Clin Cancer Res"},{"key":"4703_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.07.015","author":"JR Grandis","year":"2025","unstructured":"Grandis JR, Skorupski KA, Cheng N, Cui Z, Li H, Woerner LC, et al. Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer. Cancer Cell. 2025. https:\/\/doi.org\/10.1016\/j.ccell.2025.07.015.","journal-title":"Cancer Cell"},{"key":"4703_CR34","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/s44222-024-00231-z","volume":"2","author":"AO Omole","year":"2024","unstructured":"Omole AO, Zhao Z, Chang-Liao S, de Oliveira JFA, Boone CE, Sutorus L, Sack M, Varner J, Fiering SN, Steinmetz NF. Virus nanotechnology for intratumoural immunotherapy. Nat Rev Bioeng. 2024;2:916\u201329.","journal-title":"Nat Rev Bioeng"},{"key":"4703_CR35","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.copbio.2021.09.012","volume":"73","author":"RA Hills","year":"2022","unstructured":"Hills RA, Howarth M. Virus-like particles against infectious disease and cancer: guidance for the nano-architect. Curr Opin Biotechnol. 2022;73:346\u201354.","journal-title":"Curr Opin Biotechnol"},{"key":"4703_CR36","doi-asserted-by":"crossref","unstructured":"Dai S, Wang H, Deng FJJIS. Advances and challenges in enveloped virus-like particle (VLP)-based vaccines. 2018, 2.","DOI":"10.29245\/2578-3009\/2018\/2.1118"},{"key":"4703_CR37","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1021\/acsbiomaterials.4c00770","volume":"10","author":"P Vishwakarma","year":"2024","unstructured":"Vishwakarma P, Puri S, Banerjee M, Chang CY, Chang CC, Chaudhuri TK. Deciphering the Thermal Stability of Bacteriophage MS2-Derived Virus-like Particle and Its Engineered Variant. ACS Biomater Sci Eng. 2024;10:4812\u201322.","journal-title":"ACS Biomater Sci Eng"},{"key":"4703_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020436","author":"M Palma","year":"2023","unstructured":"Palma M. Aspects of Phage-Based Vaccines for Protein and Epitope Immunization. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines11020436.","journal-title":"Vaccines"},{"key":"4703_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.cbpa.2017.03.013","volume":"38","author":"AE Czapar","year":"2017","unstructured":"Czapar AE, Steinmetz NF. Plant viruses and bacteriophages for drug delivery in medicine and biotechnology. Curr Opin Chem Biol. 2017;38:108\u201316.","journal-title":"Curr Opin Chem Biol"},{"key":"4703_CR40","first-page":"22","volume":"4","author":"M Shahgolzari","year":"2022","unstructured":"Shahgolzari M, Fiering S. Emerging Potential of Plant Virus Nanoparticles (PVNPs) in Anticancer Immunotherapies. J Cancer Immunol (Wilmington). 2022;4:22\u20139.","journal-title":"J Cancer Immunol (Wilmington)"},{"key":"4703_CR41","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","volume":"185","author":"S Banskota","year":"2022","unstructured":"Banskota S, Raguram A, Suh S, Du SW, Davis JR, Choi EH, Wang X, Nielsen SC, Newby GA, Randolph PB, et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell. 2022;185:250\u2013e265216.","journal-title":"Cell"},{"issue":"1","key":"4703_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-021-00631-2","volume":"6","author":"L Chen","year":"2021","unstructured":"Chen L, Hong W, Ren W, Xu T, Qian Z, He Z. Recent progress in targeted delivery vectors based on biomimetic nanoparticles. Signal Transduct Target Ther. 2021;6:225.","journal-title":"Signal Transduct Target Ther"},{"key":"4703_CR43","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1016\/j.cell.2025.03.015","volume":"188","author":"J Geilenkeuser","year":"2025","unstructured":"Geilenkeuser J, Armbrust N, Steinmassl E, Du SW, Schmidt S, Binder EMH, et al. Engineered nucleocytosolic vehicles for loading of programmable editors. Cell. 2025;188:2637-2655 e2631.","journal-title":"Cell"},{"key":"4703_CR44","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/s41587-021-01124-x","volume":"39","author":"A Gutkin","year":"2021","unstructured":"Gutkin A, Rosenblum D, Peer D. RNA delivery with a human virus-like particle. Nat Biotechnol. 2021;39:1514\u20135.","journal-title":"Nat Biotechnol"},{"key":"4703_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/14760584.2020.1738227","volume":"19","author":"X Lei","year":"2020","unstructured":"Lei X, Cai X, Yang Y. Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines. Expert Rev Vaccines. 2020;19:235\u201346.","journal-title":"Expert Rev Vaccines"},{"key":"4703_CR46","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1126\/science.aaf8818","volume":"353","author":"JB Bale","year":"2016","unstructured":"Bale JB, Gonen S, Liu Y, Sheffler W, Ellis D, Thomas C, et al. Accurate design of megadalton-scale two-component icosahedral protein complexes. Science. 2016;353:389\u201394.","journal-title":"Science"},{"key":"4703_CR47","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls AC, Fiala B, Schafer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O\u2019Connor MA, Chen C, et al. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell. 2020;183:1367\u2013e13821317.","journal-title":"Cell"},{"key":"4703_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1021\/mp300240m","volume":"10","author":"S Shukla","year":"2013","unstructured":"Shukla S, Ablack AL, Wen AM, Lee KL, Lewis JD, Steinmetz NF. Increased tumor homing and tissue penetration of the filamentous plant viral nanoparticle Potato virus X. Mol Pharm. 2013;10:33\u201342.","journal-title":"Mol Pharm"},{"key":"4703_CR49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nnano.2015.292","volume":"11","author":"PH Lizotte","year":"2016","unstructured":"Lizotte PH, Wen AM, Sheen MR, Fields J, Rojanasopondist P, Steinmetz NF, et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat Nanotechnol. 2016;11:295\u2013303.","journal-title":"Nat Nanotechnol"},{"key":"4703_CR50","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1586\/erv.10.115","volume":"9","author":"A Roldao","year":"2010","unstructured":"Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Review of Vaccines. 2010;9:1149\u201376.","journal-title":"Expert Review of Vaccines"},{"key":"4703_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109439","volume":"27","author":"R Josi","year":"2024","unstructured":"Josi R, Speiser DE, de Brot S, Vogt AC, Sevick-Muraca EM, Tolstonog GV, et al. A tetravalent nanovaccine that inhibits growth of HPV-associated head and neck carcinoma via dendritic and T cell activation. iScience. 2024;27:109439.","journal-title":"iScience"},{"key":"4703_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2025.110651","volume":"611","author":"K Gackowska","year":"2025","unstructured":"Gackowska K, Krejmer-Rabalska M, Drazkowska K, Jemielity J, Krol E, Szewczyk B. Affinity-purified sHBsAg-based virus-like particles as a platform for foreign mRNA binding. Virology. 2025;611:110651.","journal-title":"Virology"},{"key":"4703_CR53","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1021\/acs.bioconjchem.7b00296","volume":"28","author":"D Patterson","year":"2017","unstructured":"Patterson D, Schwarz B, Avera J, Western B, Hicks M, Krugler P, et al. Sortase-mediated ligation as a modular approach for the covalent attachment of proteins to the exterior of the bacteriophage P22 virus-like particle. Bioconjug Chem. 2017;28:2114\u201324.","journal-title":"Bioconjug Chem"},{"key":"4703_CR54","doi-asserted-by":"publisher","first-page":"13216","DOI":"10.1021\/acs.chemrev.4c00251","volume":"124","author":"K Ghosal","year":"2024","unstructured":"Ghosal K, Bhattacharyya SK, Mishra V, Zuilhof H. Click chemistry for biofunctional polymers: from observing to steering cell behavior. Chem Rev. 2024;124:13216\u2013300.","journal-title":"Chem Rev"},{"key":"4703_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202300125","volume":"19","author":"K Cheng","year":"2023","unstructured":"Cheng K, Ma N, Liang J, Ma X, Feng Q, Liu G, et al. Site-specific modification of virus-like particles for exogenous tumor antigen display and minimizing preexisting immunity. Small. 2023;19:e2300125.","journal-title":"Small"},{"key":"4703_CR56","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1021\/bc100367u","volume":"22","author":"KG Patel","year":"2011","unstructured":"Patel KG, Swartz JR. Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry. Bioconjug Chem. 2011;22:376\u201387.","journal-title":"Bioconjug Chem"},{"key":"4703_CR57","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1021\/accountsmr.3c00050","volume":"4","author":"W Shan","year":"2023","unstructured":"Shan W, Wang C, Chen H, Ren L. Rational design of virus-like particles for nanomedicine. Acc Mater Res. 2023;4:814\u201326.","journal-title":"Acc Mater Res"},{"key":"4703_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120726","volume":"271","author":"W Li","year":"2021","unstructured":"Li W, Jing Z, Wang S, Li Q, Xing Y, Shi H, et al. P22 virus-like particles as an effective antigen delivery nanoplatform for cancer immunotherapy. Biomaterials. 2021;271:120726.","journal-title":"Biomaterials"},{"key":"4703_CR59","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1039\/D2CS01032A","volume":"52","author":"R Roy","year":"2023","unstructured":"Roy R, Mousavifar L. Carrier diversity and chemical ligations in the toolbox for designing tumor-associated carbohydrate antigens (TACAs) as synthetic vaccine candidates. Chem Soc Rev. 2023;52:3353\u201396.","journal-title":"Chem Soc Rev"},{"key":"4703_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.07.014","author":"L Neukirch","year":"2025","unstructured":"Neukirch L, Uhrig-Schmidt S, von Werthern K, Tuch A, Kraske JA, Lyu Y, et al. Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles. Mol Ther. 2025. https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.014.","journal-title":"Mol Ther"},{"key":"4703_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004022","author":"M Xiao","year":"2022","unstructured":"Xiao M, Xie L, Cao G, Lei S, Wang P, Wei Z, et al. CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1\/PD-L1 immunotherapy. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-004022.","journal-title":"J Immunother Cancer"},{"key":"4703_CR62","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.98579","author":"R Tang","year":"2024","unstructured":"Tang R, Guo L, Wei T, Chen T, Yang H, Ye H, et al. Engineering PEG10assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination. Elife. 2024. https:\/\/doi.org\/10.7554\/eLife.98579.","journal-title":"Elife"},{"key":"4703_CR63","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1016\/j.vaccine.2014.04.032","volume":"32","author":"K Kalnin","year":"2014","unstructured":"Kalnin K, Tibbitts T, Yan Y, Stegalkina S, Shen L, Costa V, Sabharwal R, Anderson SF, Day PM, Christensen N, et al. Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes. Vaccine. 2014;32:3540\u20137.","journal-title":"Vaccine"},{"key":"4703_CR64","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40364-025-00808-9","volume":"13","author":"Z Wang","year":"2025","unstructured":"Wang Z, Gu Y, Sun X, Huang H. Computation strategies and clinical applications in neoantigen discovery towards precision cancer immunotherapy. Biomark Res. 2025;13:96.","journal-title":"Biomark Res"},{"key":"4703_CR65","doi-asserted-by":"publisher","first-page":"e1869","DOI":"10.1002\/wnan.1869","volume":"15","author":"D McNeale","year":"2023","unstructured":"McNeale D, Dashti N, Cheah LC, Sainsbury F. Protein cargo encapsulation by virus-like particles: Strategies and applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023;15:e1869.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"4703_CR66","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.addr.2015.10.003","volume":"95","author":"M Somiya","year":"2015","unstructured":"Somiya M, Kuroda S. Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule. Adv Drug Deliv Rev. 2015;95:77\u201389.","journal-title":"Adv Drug Deliv Rev"},{"key":"4703_CR67","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1021\/acs.nanolett.4c04541","volume":"25","author":"C Ma","year":"2025","unstructured":"Ma C, Yang M, Zhou W, Guo S, Zhang H, Gong J, Zhang XE, Li F. The RNA Landscape of In Vivo-Assembled MS2 Virus-Like Particles as mRNA Carriers Reveals RNA Contamination from Host Viruses. Nano Lett. 2025;25:3038\u201344.","journal-title":"Nano Lett"},{"key":"4703_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1651594","volume":"16","author":"G Zhou","year":"2025","unstructured":"Zhou G, Luo Z, Zhang Z, Cao S, Li Y. MS2 Virus-Like Particles as a Versatile Platform for Multi-Disease Vaccines: A Review. Frontiers in Immunology. 2025;16:1651594.","journal-title":"Frontiers in Immunology"},{"key":"4703_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/v14091905","author":"J He","year":"2022","unstructured":"He J, Yu L, Lin X, Liu X, Zhang Y, Yang F, et al. Virus-like Particles as Nanocarriers for Intracellular Delivery of Biomolecules and Compounds. Viruses. 2022. https:\/\/doi.org\/10.3390\/v14091905.","journal-title":"Viruses"},{"key":"4703_CR70","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jconrel.2024.12.034","volume":"378","author":"Z Wang","year":"2025","unstructured":"Wang Z, Liu S, Ming R, Wang W, Wang C, Li C, Yang J, Zhang F, Lu G, Mei L, Huang LL. Engineered virus-mimicking nanovaccine with lymph node-tumor dual-targeting and STING-activating capacity for robust cancer immunotherapy. J Control Release. 2025;378:416\u201327.","journal-title":"J Control Release"},{"key":"4703_CR71","doi-asserted-by":"publisher","first-page":"53682","DOI":"10.1021\/acsami.0c16012","volume":"12","author":"K Cheng","year":"2020","unstructured":"Cheng K, Du T, Li Y, Qi Y, Min H, Wang Y, Zhang Q, Wang C, Zhou Y, Li L, et al. Dual-Antigen-Loaded Hepatitis B Virus Core Antigen Virus-like Particles Stimulate Efficient Immunotherapy Against Melanoma. ACS Appl Mater Interfaces. 2020;12:53682\u201390.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4703_CR72","volume":"18","author":"L Jiang","year":"2023","unstructured":"Jiang L, Qi Y, Yang L, Miao Y, Ren W, Liu H, et al. Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment. Asian J Pharm Sci. 2023;18:100852.","journal-title":"Asian J Pharm Sci"},{"key":"4703_CR73","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1021\/mp3002733","volume":"9","author":"F Danhier","year":"2012","unstructured":"Danhier F, Le Breton A, Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm. 2012;9:2961\u201373.","journal-title":"Mol Pharm"},{"key":"4703_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2021.111623","volume":"201","author":"S Fu","year":"2021","unstructured":"Fu S, Zhao Y, Sun J, Yang T, Zhi D, Zhang E, et al. Integrin \u03b1v\u03b23-targeted liposomal drug delivery system for enhanced lung cancer therapy. Colloids Surf B Biointerfaces. 2021;201:111623.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"4703_CR75","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00259-020-05094-1","volume":"48","author":"B Altunay","year":"2021","unstructured":"Altunay B, Morgenroth A, Beheshti M, Vogg A, Wong NCL, Ting HH, et al. HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. Eur J Nucl Med Mol Imaging. 2021;48:1371\u201389.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4703_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/nano15030158","author":"A Spada","year":"2025","unstructured":"Spada A, Gerber-Lemaire S. Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting. Nanomaterials. 2025. https:\/\/doi.org\/10.3390\/nano15030158.","journal-title":"Nanomaterials"},{"key":"4703_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.145125","volume":"318","author":"Y Verma","year":"2025","unstructured":"Verma Y, Khan I, Dongsar TT, Alsayari A, Wahab S, Sahebkar A, et al. AS1411 aptamer based nanomaterials: A novel approach for breast cancer therapy. Int J Biol Macromol. 2025;318:145125.","journal-title":"Int J Biol Macromol"},{"key":"4703_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13010069","author":"S Balkhi","year":"2025","unstructured":"Balkhi S, Bilato G, De Lerma Barbaro A, Orecchia P, Poggi A, Mortara L. Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies. Vaccines. 2025. https:\/\/doi.org\/10.3390\/vaccines13010069.","journal-title":"Vaccines"},{"key":"4703_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202002214","volume":"10","author":"B Uricoli","year":"2021","unstructured":"Uricoli B, Birnbaum LA, Do P, Kelvin JM, Jain J, Costanza E, et al. Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy. Adv Healthc Mater. 2021;10:e2002214.","journal-title":"Adv Healthc Mater"},{"key":"4703_CR80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13346-014-0210-2","volume":"5","author":"D Shan","year":"2015","unstructured":"Shan D, Li J, Cai P, Prasad P, Liu F, Rauth AM, Wu XY. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of alphavbeta3 integrin-overexpressing breast cancer cells. Drug Deliv Transl Res. 2015;5:15\u201326.","journal-title":"Drug Deliv Transl Res"},{"key":"4703_CR81","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jconrel.2024.07.056","volume":"373","author":"J Zheng","year":"2024","unstructured":"Zheng J, Wang M, Pang L, Wang S, Kong Y, Zhu X, et al. Identification of a novel DEC-205 binding peptide to develop dendritic cell-targeting nanovaccine for cancer immunotherapy. J Control Release. 2024;373:568\u201382.","journal-title":"J Control Release"},{"key":"4703_CR82","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jconrel.2019.02.016","volume":"301","author":"R Zaman","year":"2019","unstructured":"Zaman R, Islam RA, Ibnat N, Othman I, Zaini A, Lee CY, et al. Current strategies in extending half-lives of therapeutic proteins. J Control Release. 2019;301:176\u201389.","journal-title":"J Control Release"},{"key":"4703_CR83","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.copbio.2018.11.017","volume":"60","author":"L Van Landuyt","year":"2019","unstructured":"Van Landuyt L, Lonigro C, Meuris L, Callewaert N. Customized protein glycosylation to improve biopharmaceutical function and targeting. Curr Opin Biotechnol. 2019;60:17\u201328.","journal-title":"Curr Opin Biotechnol"},{"key":"4703_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/ph18071042","author":"X Zhao","year":"2025","unstructured":"Zhao X, Li Y. Matrix Metalloproteinase-2-Responsive Peptide-Modified Cleavable PEGylated Liposomes for Paclitaxel Delivery. Pharmaceuticals (Basel). 2025. https:\/\/doi.org\/10.3390\/ph18071042.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4703_CR85","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.170063","volume":"4","author":"L Li","year":"2017","unstructured":"Li L, Zhang Y, Wang J. Effects of ligand distribution on receptor-diffusion-mediated cellular uptake of nanoparticles. R Soc Open Sci. 2017;4:170063.","journal-title":"R Soc Open Sci"},{"key":"4703_CR86","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/smll.201401952","volume":"11","author":"L Shen","year":"2015","unstructured":"Shen L, Zhou J, Wang Y, Kang N, Ke X, Bi S, et al. Efficient encapsulation of Fe(3)O(4) nanoparticles into genetically engineered hepatitis B core virus-like particles through a specific interaction for potential bioapplications. Small. 2015;11:1190\u20136.","journal-title":"Small"},{"key":"4703_CR87","doi-asserted-by":"crossref","unstructured":"Uchida M, Brunk NE, Hewagama ND, Lee B, Prevelige PE Jr., Jadhao V, et al. Multilayered Ordered Protein Arrays Self-Assembled from a Mixed Population of Virus-like Particles. ACS Nano. 2022;16:7662\u201373.","DOI":"10.1021\/acsnano.1c11272"},{"key":"4703_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202101717","volume":"17","author":"W Zhang","year":"2021","unstructured":"Zhang W, Jia Q, Teng Y, Yang M, Zhang H, Zhang XE, et al. An Ultrastable Virus-Like Particle with a Carbon Dot Core and Expanded Sequence Plasticity. Small. 2021;17:2101717.","journal-title":"Small"},{"key":"4703_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2024.114418","volume":"247","author":"KR Kim","year":"2025","unstructured":"Kim KR, Lee AS, Heo HR, Park SY, Kim CS. Bioinspired synthesis of virus-like particle-templated thin silica-layered nanocages with enhanced biocompatibility and cellular uptake as drug delivery carriers. Colloids Surf B Biointerfaces. 2025;247:114418.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"4703_CR90","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jviromet.2019.04.013","volume":"270","author":"KM Ricks","year":"2019","unstructured":"Ricks KM, Shoemaker CJ, Dupuy LC, Flusin O, Voorhees MA, Fulmer AN, et al. Development of a bead-based immunoassay using virus-like particles for detection of alphaviral humoral response. J Virol Methods. 2019;270:12\u20137.","journal-title":"J Virol Methods"},{"key":"4703_CR91","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1039\/D3TB00469D","volume":"11","author":"I Trashi","year":"2023","unstructured":"Trashi I, Durbacz MZ, Trashi O, Wijesundara YH, Ehrman RN, Chiev AC, et al. Self-assembly of a fluorescent virus-like particle for imaging in tissues with high autofluorescence. J Mater Chem B. 2023;11:4445\u201352.","journal-title":"J Mater Chem B"},{"key":"4703_CR92","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jconrel.2022.05.056","volume":"348","author":"H Ding","year":"2022","unstructured":"Ding H, Tan P, Fu S, Tian X, Zhang H, Ma X, et al. Preparation and application of pH-responsive drug delivery systems. J Control Release. 2022;348:206\u201338.","journal-title":"J Control Release"},{"key":"4703_CR93","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1080\/17425247.2022.2135502","volume":"19","author":"C Lopes","year":"2022","unstructured":"Lopes C, Cristovao J, Silverio V, Lino PR, Fonte P. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications. Expert Opinion on Drug Delivery. 2022;19:1381\u201395.","journal-title":"Expert Opinion on Drug Delivery"},{"key":"4703_CR94","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1021\/acs.molpharmaceut.6b00072","volume":"13","author":"S Saboo","year":"2016","unstructured":"Saboo S, Tumban E, Peabody J, Wafula D, Peabody DS, Chackerian B, et al. Optimized formulation of a thermostable spray-dried virus-like particle vaccine against human papillomavirus. Mol Pharm. 2016;13:1646\u201355.","journal-title":"Mol Pharm"},{"key":"4703_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1579","volume":"12","author":"MO Mohsen","year":"2020","unstructured":"Mohsen MO, Speiser DE, Knuth A, Bachmann MF. Virus-like particles for vaccination against cancer. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12:e1579.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"4703_CR96","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s12276-023-00977-3","volume":"55","author":"JH Oh","year":"2023","unstructured":"Oh JH, Cho JY. Comparative oncology: overcoming human cancer through companion animal studies. Exp Mol Med. 2023;55:725\u201334.","journal-title":"Exp Mol Med"},{"issue":"1","key":"4703_CR97","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40425-016-0200-7","volume":"4","author":"JS Park","year":"2016","unstructured":"Park JS, Withers SS, Modiano JF, Kent MS, Chen M, Luna JI, et al. Canine cancer immunotherapy studies: linking mouse and human. Journal for ImmunoTherapy of Cancer. 2016;4:97.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"4703_CR98","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/CJI.0b013e31818f13c4","volume":"32","author":"R Cubas","year":"2009","unstructured":"Cubas R, Zhang S, Kwon S, Sevick-Muraca EM, Li M, Chen C, et al. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother. 2009;32:118\u201328.","journal-title":"J Immunother"},{"key":"4703_CR99","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/14760584.2022.2029415","volume":"21","author":"H McFall-Boegeman","year":"2022","unstructured":"McFall-Boegeman H, Huang X. Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines. Expert Review of Vaccines. 2022;21:453\u201369.","journal-title":"Expert Review of Vaccines"},{"key":"4703_CR100","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","volume":"11","author":"A Ribas","year":"2021","unstructured":"Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, et al. Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma. Cancer Discov. 2021;11:2998\u20133007.","journal-title":"Cancer Discov"},{"key":"4703_CR101","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer. 2022;3:1452\u201363.","journal-title":"Nat Cancer"},{"key":"4703_CR102","doi-asserted-by":"publisher","first-page":"nwad310","DOI":"10.1093\/nsr\/nwad310","volume":"11","author":"Z Huang","year":"2024","unstructured":"Huang Z, Zhuang X, Liu L, Zhao J, Ma S, Si X, Zhu Z, Wu F, Jin N, Tian M, et al. Modularized viromimetic polymer nanoparticle vaccines (VPNVaxs) to elicit durable and effective humoral immune responses. Natl Sci Rev. 2024;11:nwad310.","journal-title":"Natl Sci Rev"},{"key":"4703_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0270-1","volume":"5","author":"B Donaldson","year":"2017","unstructured":"Donaldson B, Al-Barwani F, Pelham SJ, Young K, Ward VK, Young SL. Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer. Journal for ImmunoTherapy of Cancer. 2017;5:69.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"4703_CR104","doi-asserted-by":"publisher","first-page":"10482","DOI":"10.1021\/acsnano.2c01283","volume":"16","author":"M Li","year":"2022","unstructured":"Li M, Liang Z, Chen C, Yu G, Yao Z, Guo Y, et al. Virus-like particle-templated silica-adjuvanted nanovaccines with enhanced humoral and cellular immunity. ACS Nano. 2022;16:10482\u201395.","journal-title":"ACS Nano"},{"key":"4703_CR105","doi-asserted-by":"publisher","first-page":"e43248","DOI":"10.1371\/journal.pone.0043248","volume":"7","author":"R Sharma","year":"2012","unstructured":"Sharma R, Ghasparian A, Robinson JA, McCullough KC. Synthetic virus-like particles target dendritic cell lipid rafts for rapid endocytosis primarily but not exclusively by macropinocytosis. PLoS ONE. 2012;7:e43248.","journal-title":"PLoS ONE"},{"key":"4703_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113603","volume":"381","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Cao S, Li H, Zhang Z, Lu Q, Li H, et al. Myeloid-derived suppressor cell-targeted virus-like particles synergistically activate innate immune response for cancer immunotherapy. J Control Release. 2025;381:113603.","journal-title":"J Control Release"},{"key":"4703_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1504124","volume":"15","author":"W Ning","year":"2024","unstructured":"Ning W, Yan S, Song Y, Xu H, Zhang J, Wang X. Virus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response. Front Immunol. 2024;15:1504124.","journal-title":"Front Immunol"},{"key":"4703_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01238-x","volume":"19","author":"SY Wu","year":"2020","unstructured":"Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19:120.","journal-title":"Mol Cancer"},{"key":"4703_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1638102","volume":"16","author":"OV Kovaleva","year":"2025","unstructured":"Kovaleva OV, Rashidova MA, Sinyov VV, Malashenko OS, Gratchev A. M1 macrophages - unexpected contribution to tumor progression. Front Immunol. 2025;16:1638102.","journal-title":"Front Immunol"},{"key":"4703_CR110","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-024-05191-6","volume":"81","author":"G Li","year":"2024","unstructured":"Li G, Zhao X, Zheng Z, Zhang H, Wu Y, Shen Y, et al. cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors. Cell Mol Life Sci. 2024;81:149.","journal-title":"Cell Mol Life Sci"},{"key":"4703_CR111","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm9409","volume":"7","author":"E Kvedaraite","year":"2022","unstructured":"Kvedaraite E, Ginhoux F. Human dendritic cells in cancer. Sci Immunol. 2022;7:eabm9409.","journal-title":"Sci Immunol"},{"key":"4703_CR112","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/eji.201142064","volume":"42","author":"M Braun","year":"2012","unstructured":"Braun M, Jandus C, Maurer P, Hammann-Haenni A, Schwarz K, Bachmann MF, et al. Virus-like particles induce robust human T-helper cell responses. Eur J Immunol. 2012;42:330\u201340.","journal-title":"Eur J Immunol"},{"key":"4703_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0111-y","volume":"4","author":"AI Makarkov","year":"2019","unstructured":"Makarkov AI, Golizeh M, Ruiz-Lancheros E, Gopal AA, Costas-Cancelas IN, Chierzi S, et al. Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages. NPJ Vaccines. 2019;4:17.","journal-title":"NPJ Vaccines"},{"key":"4703_CR114","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, Gogenur I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124:359\u201367.","journal-title":"Br J Cancer"},{"key":"4703_CR115","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.imlet.2021.09.002","volume":"239","author":"AJ Jimenez-Chavez","year":"2021","unstructured":"Jimenez-Chavez AJ, Nava-Garcia BK, Bustos-Jaimes I, Moreno-Fierros L. B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer. Immunol Lett. 2021;239:77\u201387.","journal-title":"Immunol Lett"},{"key":"4703_CR116","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40259-023-00618-1","volume":"37","author":"W Lee","year":"2023","unstructured":"Lee W, Lee SM, Jung ST. Unlocking the power of complement-dependent cytotoxicity: engineering strategies for the development of potent therapeutic antibodies for cancer treatments. BioDrugs. 2023;37:637\u201348.","journal-title":"BioDrugs"},{"key":"4703_CR117","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/imr.13265","volume":"319","author":"CM Van Wagoner","year":"2023","unstructured":"Van Wagoner CM, Rivera-Escalera F, Jaimes-Delgadillo NC, Chu CC, Zent CS, Elliott MR. Antibody-mediated phagocytosis in cancer immunotherapy. Immunol Rev. 2023;319:128\u201341.","journal-title":"Immunol Rev"},{"key":"4703_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061492","author":"V Rolih","year":"2020","unstructured":"Rolih V, Caldeira J, Bolli E, Salameh A, Conti L, Barutello G, et al. Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12061492.","journal-title":"Cancers (Basel)"},{"key":"4703_CR119","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu Z, Leet DE, Allesoe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021;27:515\u201325.","journal-title":"Nat Med"},{"key":"4703_CR120","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/cac2.12416","volume":"43","author":"A Goenka","year":"2023","unstructured":"Goenka A, Khan F, Verma B, Sinha P, Dmello CC, Jogalekar MP, et al. Tumor microenvironment signaling and therapeutics in cancer progression. Cancer Commun (Lond). 2023;43:525\u201361.","journal-title":"Cancer Commun (Lond)"},{"key":"4703_CR121","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340.","journal-title":"J Clin Invest"},{"key":"4703_CR122","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"Y-T Liu","year":"2021","unstructured":"Liu Y-T, Sun Z-J. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics (Basel). 2021;11:5365.","journal-title":"Theranostics (Basel)"},{"key":"4703_CR123","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House IG, Savas P, Lai J, Chen AX, Oliver AJ, Teo ZL, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020;26:487\u2013504.","journal-title":"Clin Cancer Res"},{"key":"4703_CR124","doi-asserted-by":"publisher","first-page":"e2301281","DOI":"10.1002\/smll.202301281","volume":"19","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Dong J, Wang J, Wang J, Wang C, Li Y, Chen XL, Wang X, Shan W, Fu G, Ren L. Integration of Protein Nanocage with CpG Motifs: A Virus-Mimicked Core-Shell Nanostructure to Ignite Antitumor Immunity. Small. 2023;19:e2301281.","journal-title":"Small"},{"key":"4703_CR125","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u20137.","journal-title":"Cancer Treat Rev"},{"key":"4703_CR126","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9:274.","journal-title":"Signal Transduct Target Ther"},{"key":"4703_CR127","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-023-01473-x","volume":"16","author":"X Cheng","year":"2023","unstructured":"Cheng X, Wang H, Wang Z, Zhu B, Long H. Tumor-associated myeloid cells in cancer immunotherapy. J Hematol Oncol. 2023;16:71.","journal-title":"J Hematol Oncol"},{"key":"4703_CR128","doi-asserted-by":"publisher","first-page":"17826","DOI":"10.1021\/acsnano.3c03387","volume":"17","author":"W Yan","year":"2023","unstructured":"Yan W, Li Y, Zou Y, Zhu R, Wu T, Sun X, Yuan W, Lang T, Yin Q, Li Y. Breaking Tumor Immunosuppressive Network by Regulating Multiple Nodes with Triadic Drug Delivery Nanoparticles. ACS Nano. 2023;17:17826\u201344.","journal-title":"ACS Nano"},{"key":"4703_CR129","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, Lin L. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol. 2024;8:31.","journal-title":"NPJ Precis Oncol"},{"key":"4703_CR130","doi-asserted-by":"publisher","first-page":"896228","DOI":"10.3389\/fimmu.2022.896228","volume":"13","author":"A Ramirez-Labrada","year":"2022","unstructured":"Ramirez-Labrada A, Pesini C, Santiago L, Hidalgo S, Calvo-Perez A, Onate C, Andres-Tovar A, Garzon-Tituana M, Uranga-Murillo I, Arias MA, et al. All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity. Front Immunol. 2022;13:896228.","journal-title":"Front Immunol"},{"key":"4703_CR131","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41590-024-01789-x","volume":"25","author":"Y Xia","year":"2024","unstructured":"Xia Y, Li X, Bie N, Pan W, Miao YR, Yang M, Gao Y, Chen C, Liu H, Gan L, Guo AY. A method for predicting drugs that can boost the efficacy of immune checkpoint blockade. Nat Immunol. 2024;25:659\u201370.","journal-title":"Nat Immunol"},{"key":"4703_CR132","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/14760584.2018.1506332","volume":"17","author":"JM Collins","year":"2018","unstructured":"Collins JM, Redman JM, Gulley JL. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy. Expert Rev Vaccines. 2018;17:697\u2013705.","journal-title":"Expert Rev Vaccines"},{"key":"4703_CR133","doi-asserted-by":"publisher","first-page":"34063","DOI":"10.1021\/acsnano.4c09653","volume":"18","author":"W Wang","year":"2024","unstructured":"Wang W, Zou C, Liu X, He L, Cao Z, Zhu M, Wu Y, Liu X, Ma J, Wang Y, et al. Biomimetic Dendritic Cell-Based Nanovaccines for Reprogramming the Immune Microenvironment to Boost Tumor Immunotherapy. ACS Nano. 2024;18:34063\u201376.","journal-title":"ACS Nano"},{"key":"4703_CR134","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","volume":"48","author":"SA Patel","year":"2018","unstructured":"Patel SA, Minn AJ. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity. 2018;48:417\u201333.","journal-title":"Immunity"},{"key":"4703_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112724","author":"Y Hao","year":"2022","unstructured":"Hao Y, Gu Z, Yu Z, Schomann T, Sayedipour S, Aguilar JC, et al. Photodynamic Therapy in Combination with the Hepatitis B Core Virus-like Particles (HBc VLPs) to Prime Anticancer Immunity for Colorectal Cancer Treatment. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14112724.","journal-title":"Cancers (Basel)"},{"key":"4703_CR136","doi-asserted-by":"publisher","first-page":"10407","DOI":"10.1021\/acsnano.3c01102","volume":"17","author":"HH Pang","year":"2023","unstructured":"Pang HH, Huang CY, Chen PY, Li NS, Hsu YP, Wu JK, Fan HF, Wei KC, Yang HW. Bioengineered Bacteriophage-Like Nanoparticles as RNAi Therapeutics to Enhance Radiotherapy against Glioblastomas. ACS Nano. 2023;17:10407\u201322.","journal-title":"ACS Nano"},{"key":"4703_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28227679","author":"H Li","year":"2023","unstructured":"Li H, Zhu Y, Wang X, Feng Y, Qian Y, Ma Q, et al. Joining Forces: The Combined Application of Therapeutic Viruses and Nanomaterials in Cancer Therapy. Molecules. 2023. https:\/\/doi.org\/10.3390\/molecules28227679.","journal-title":"Molecules"},{"key":"4703_CR138","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ctrv.2015.11.005","volume":"42","author":"MT Madondo","year":"2016","unstructured":"Madondo MT, Quinn M, Plebanski M. Low dose cyclophosphamide: Mechanisms of T cell modulation. Cancer Treat Rev. 2016;42:3\u20139.","journal-title":"Cancer Treat Rev"},{"key":"4703_CR139","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-17-0895","volume":"23","author":"M Scurr","year":"2017","unstructured":"Scurr M, Pembroke T, Bloom A, Roberts D, Thomson A, Smart K, Bridgeman H, Adams R, Brewster A, Jones R, et al. Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer. Clin Cancer Res. 2017;23:6771\u201380.","journal-title":"Clin Cancer Res"},{"key":"4703_CR140","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41551-024-01208-4","volume":"9","author":"D Yin","year":"2025","unstructured":"Yin D, Zhong Y, Ling S, Lu S, Wang X, Jiang Z, Wang J, Dai Y, Tian X, Huang Q, et al. Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers. Nat Biomed Eng. 2025;9:185\u2013200.","journal-title":"Nat Biomed Eng"},{"key":"4703_CR141","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1039\/D2TB02163C","volume":"11","author":"C Wang","year":"2023","unstructured":"Wang C, Xiao C, Chen Y, Li Y, Zhang Q, Shan W, Li Y, Bi S, Wang Y, Wang X, Ren L. Sequential administration of virus-like particle-based nanomedicine to elicit enhanced tumor chemotherapy. J Mater Chem B. 2023;11:2674\u201383.","journal-title":"J Mater Chem B"},{"key":"4703_CR142","doi-asserted-by":"publisher","first-page":"45613","DOI":"10.1021\/acsami.5c12494","volume":"17","author":"A Simms","year":"2025","unstructured":"Simms A, Affonso de Oliveira JF, Steinmetz NF. STING Agonist-Loaded Physalis Mottle Virus-like Particles as a Potent Prophylactic for Metastatic Melanoma. ACS Appl Mater Interfaces. 2025;17:45613\u201324.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4703_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62425-0","volume":"14","author":"N MacDonald","year":"2024","unstructured":"MacDonald N, Raven N, Diep W, Evans S, Pannipitiya S, Bramwell G, et al. The molecular evolution of cancer associated genes in mammals. Sci Rep. 2024;14:11650.","journal-title":"Sci Rep"},{"key":"4703_CR144","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.tvjl.2015.10.008","volume":"207","author":"D Regan","year":"2016","unstructured":"Regan D, Guth A, Coy J, Dow S. Cancer immunotherapy in veterinary medicine: Current options and new developments. Vet J. 2016;207:20\u20138.","journal-title":"Vet J"},{"key":"4703_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030799","author":"G Barutello","year":"2018","unstructured":"Barutello G, Rolih V, Arigoni M, Tarone L, Conti L, Quaglino E, et al. Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs\u2019 Revolution for Immunotherapy. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19030799.","journal-title":"Int J Mol Sci"},{"key":"4703_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/vetsci10050336","author":"JN Hambly","year":"2023","unstructured":"Hambly JN, Ruby CE, Mourich DV, Bracha S, Dolan BP. Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary Oncology. Veterinary Sciences. 2023. https:\/\/doi.org\/10.3390\/vetsci10050336.","journal-title":"Veterinary Sciences"},{"key":"4703_CR147","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1158\/1535-7163.MCT-13-0288","volume":"13","author":"J Singer","year":"2014","unstructured":"Singer J, Fazekas J, Wang W, Weichselbaumer M, Matz M, Mader A, et al. Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients. Mol Cancer Ther. 2014;13:1777\u201390.","journal-title":"Mol Cancer Ther"},{"key":"4703_CR148","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040785","author":"S Pantelyushin","year":"2021","unstructured":"Pantelyushin S, Ranninger E, Guerrera D, Hutter G, Maake C, Markkanen E, et al. Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13040785.","journal-title":"Cancers (Basel)"},{"key":"4703_CR149","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1146\/annurev-biodatasci-102423-111936","volume":"7","author":"JA Cahill","year":"2024","unstructured":"Cahill JA, Smith LA, Gottipati S, Torabi TS, Graim K. Bringing the Genomic Revolution to Comparative Oncology: Human and Dog Cancers. Annu Rev Biomed Data Sci. 2024;7:107\u201329.","journal-title":"Annu Rev Biomed Data Sci"},{"key":"4703_CR150","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2022.803093","volume":"9","author":"L Tarone","year":"2022","unstructured":"Tarone L, Giacobino D, Camerino M, Ferrone S, Buracco P, Cavallo F, et al. Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research. Front Vet Sci. 2022;9:803093.","journal-title":"Front Vet Sci"},{"key":"4703_CR151","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.neo.2021.06.008","volume":"23","author":"AP Lundberg","year":"2021","unstructured":"Lundberg AP, Boudreau MW, Selting KA, Chatkewitz LE, Samuelson J, Francis JM, et al. Utilizing feline oral squamous cell carcinoma patients to develop NQO1-targeted therapy. Neoplasia. 2021;23:811\u201322.","journal-title":"Neoplasia"},{"key":"4703_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/vetsci6010015","author":"RM Almela","year":"2019","unstructured":"Almela RM, Anson A. A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma. Vet Sci. 2019. https:\/\/doi.org\/10.3390\/vetsci6010015.","journal-title":"Vet Sci"},{"key":"4703_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2021.695222","volume":"8","author":"S Saellstrom","year":"2021","unstructured":"Saellstrom S, Sadeghi A, Eriksson E, Segall T, Dimopoulou M, Korsgren O, et al. Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up. Front Vet Sci. 2021;8:695222.","journal-title":"Front Vet Sci"},{"key":"4703_CR154","doi-asserted-by":"publisher","DOI":"10.3390\/v12020126","author":"JK Ho","year":"2020","unstructured":"Ho JK, Jeevan-Raj B, Netter HJ. Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms. Viruses. 2020. https:\/\/doi.org\/10.3390\/v12020126.","journal-title":"Viruses"},{"key":"4703_CR155","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.3748\/wjg.v27.i36.6025","volume":"27","author":"E Amponsah-Dacosta","year":"2021","unstructured":"Amponsah-Dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030? World J Gastroenterol. 2021;27:6025\u201338.","journal-title":"World J Gastroenterol"},{"key":"4703_CR156","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.canlet.2009.08.024","volume":"286","author":"A Plymoth","year":"2009","unstructured":"Plymoth A, Viviani S, Hainaut P. Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Lett. 2009;286:15\u201321.","journal-title":"Cancer Lett"},{"key":"4703_CR157","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.biopha.2014.12.041","volume":"70","author":"S Ramakrishnan","year":"2015","unstructured":"Ramakrishnan S, Partricia S, Mathan G. Overview of high-risk HPV\u2019s 16 and 18 infected cervical cancer: pathogenesis to prevention. Biomed Pharmacother. 2015;70:103\u201310.","journal-title":"Biomed Pharmacother"},{"key":"4703_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030391","author":"L Cheng","year":"2020","unstructured":"Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 2020. https:\/\/doi.org\/10.3390\/vaccines8030391.","journal-title":"Vaccines (Basel)"},{"key":"4703_CR159","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jadohealth.2010.01.016","volume":"46","author":"AK Chaturvedi","year":"2010","unstructured":"Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46:S20\u201326.","journal-title":"J Adolesc Health"},{"key":"4703_CR160","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.2014","author":"PY Wen","year":"2022","unstructured":"Wen PY, Reardon DA, Forst DA, Lee EQ, Haas B, Daoud T, et al. Evaluation of tumor responses and overall survival in patients with recurrent glioblastoma (GBM) from a phase IIa trial of a CMV vaccine immunotherapeutic candidate (VBI-1901). J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.2014.","journal-title":"J Clin Oncol"},{"key":"4703_CR161","doi-asserted-by":"publisher","first-page":"e1514921","DOI":"10.1080\/2162402X.2018.1514921","volume":"8","author":"M Rahman","year":"2019","unstructured":"Rahman M, Dastmalchi F, Karachi A, Mitchell D. The role of CMV in glioblastoma and implications for immunotherapeutic strategies. Oncoimmunology. 2019;8:e1514921.","journal-title":"Oncoimmunology"},{"key":"4703_CR162","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1002\/eji.201142361","volume":"42","author":"SM Goldinger","year":"2012","unstructured":"Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, et al. Nano-particle vaccination combined with TLR-7 and \u2212\u20099 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. Eur J Immunol. 2012;42:3049\u201361.","journal-title":"Eur J Immunol"},{"key":"4703_CR163","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/CJI.0b013e3181f1d614","volume":"33","author":"DE Speiser","year":"2010","unstructured":"Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W, et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother. 2010;33:848\u201358.","journal-title":"J Immunother"},{"key":"4703_CR164","first-page":"76","volume":"28","author":"S Besson","year":"2023","unstructured":"Besson S, Boucher E, Laurin D, Manches O, Aspord C, Hannani D, et al. Stimulation of the immune system by a tumor antigen-bearing adenovirus-inspired VLP allows control of melanoma growth. Molecular Therapy. 2023;28:76\u201389.","journal-title":"Molecular Therapy"},{"key":"4703_CR165","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1002\/cpz1.55","volume":"1","author":"D Sari-Ak","year":"2021","unstructured":"Sari-Ak D, Bufton J, Gupta K, Garzoni F, Fitzgerald D, Schaffitzel C, Berger I. VLP-factory and ADDomer((c)): Self-assembling Virus-Like Particle (VLP) Technologies for Multiple Protein and Peptide Epitope Display. Curr Protoc. 2021;1:e55.","journal-title":"Curr Protoc"},{"key":"4703_CR166","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","volume":"23","author":"CL Lorentzen","year":"2022","unstructured":"Lorentzen CL, Haanen JB, Met O, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022;23:e450\u20138.","journal-title":"Lancet Oncol"},{"key":"4703_CR167","doi-asserted-by":"crossref","unstructured":"Klinghammer K, Saba N, Castelluci E, Colevas A, Rutkowski T, Greil R, Thurner D, M\u00fcller-Richter U, Di Giacomo A, Grewal JJI-O. Technology: 155P BNT113\u2009+\u2009pembrolizumab as first-line treatment in patients with unresectable recurrent\/metastatic HNSCC: preliminary safety data from AHEAD-MERIT. Immuno-Oncol Technol. 2022;16:100267.","DOI":"10.1016\/j.iotech.2022.100267"},{"key":"4703_CR168","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1038\/s41467-020-16639-1","volume":"11","author":"D Wang","year":"2020","unstructured":"Wang D, Liu X, Wei M, Qian C, Song S, Chen J, Wang Z, Xu Q, Yang Y, He M, et al. Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. Nat Commun. 2020;11:2841.","journal-title":"Nat Commun"},{"key":"4703_CR169","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050463","author":"K Campbell","year":"2021","unstructured":"Campbell K, Young VL, Donaldson BC, Woodall MJ, Shields NJ, Walker GF, et al. Delivering Two Tumour Antigens Survivin and Mucin-1 on Virus-Like Particles Enhances Anti-Tumour Immune Responses. Vaccines (Basel). 2021. https:\/\/doi.org\/10.3390\/vaccines9050463.","journal-title":"Vaccines (Basel)"},{"key":"4703_CR170","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s12032-025-02986-w","volume":"42","author":"D Singh","year":"2025","unstructured":"Singh D, Singh S, Tandon N. Multi-epitope ligand-conjugated nanoparticles for tumor neoantigen targeting: advancing molecular precision in cancer immunotherapy. Med Oncol. 2025;42:424.","journal-title":"Med Oncol"},{"key":"4703_CR171","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-025-01496-6","author":"M Feng","year":"2025","unstructured":"Feng M, Ma Q, Zhang B, Chen Y, Yang Y, He X, et al. Targeting the poliovirus receptor to activate T cells and induce myeloid-derived suppressor cells to differentiate to pro-inflammatory macrophages via the IFN-\u03b3-p-STAT1-IRF8 axis in cancer therapy. Cell Death Differ. 2025. https:\/\/doi.org\/10.1038\/s41418-025-01496-6.","journal-title":"Cell Death Differ"},{"key":"4703_CR172","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/j.vaccine.2013.02.042","volume":"31","author":"JM Moffat","year":"2013","unstructured":"Moffat JM, Cheong WS, Villadangos JA, Mintern JD, Netter HJ. Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells. Vaccine. 2013;31:2310\u20136.","journal-title":"Vaccine"},{"key":"4703_CR173","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/btm2.10049","volume":"2","author":"MJ Rohovie","year":"2017","unstructured":"Rohovie MJ, Nagasawa M, Swartz JR. Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery. Bioeng Transl Med. 2017;2:43\u201357.","journal-title":"Bioeng Transl Med"},{"key":"4703_CR174","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.nano.2017.12.002","volume":"14","author":"W Shan","year":"2018","unstructured":"Shan W, Zhang D, Wu Y, Lv X, Hu B, Zhou X, Ye S, Bi S, Ren L, Zhang X. Modularized peptides modified HBc virus-like particles for encapsulation and tumor-targeted delivery of doxorubicin. Nanomedicine. 2018;14:725\u201334.","journal-title":"Nanomedicine"},{"key":"4703_CR175","doi-asserted-by":"publisher","first-page":"e2000077","DOI":"10.1002\/biot.202000077","volume":"15","author":"H Hu","year":"2020","unstructured":"Hu H, Steinmetz NF. Doxorubicin-Loaded Physalis Mottle Virus Particles Function as a pH-Responsive Prodrug Enabling Cancer Therapy. Biotechnol J. 2020;15:e2000077.","journal-title":"Biotechnol J"},{"key":"4703_CR176","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201908743","author":"H Cai","year":"2020","unstructured":"Cai H, Shukla S, Steinmetz NF. The Antitumor Efficacy of CpG Oligonucleotides is Improved by Encapsulation in Plant Virus-Like Particles. Adv Funct Mater. 2020. https:\/\/doi.org\/10.1002\/adfm.201908743.","journal-title":"Adv Funct Mater"},{"key":"4703_CR177","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006718","author":"L Secli","year":"2023","unstructured":"Secli L, Infante L, Nocchi L, De Lucia M, Cotugno G, Leoni G, et al. Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-006718.","journal-title":"J Immunother Cancer"},{"key":"4703_CR178","doi-asserted-by":"publisher","first-page":"17320","DOI":"10.1021\/acsnano.3c05288","volume":"17","author":"Y Li","year":"2023","unstructured":"Li Y, Deng K, Shen C, Liang X, Zeng Z, Liu L, Xu X. Enantiomeric Virus-Inspired Oncolytic Particles for Efficient Antitumor Immunotherapy. ACS Nano. 2023;17:17320\u201331.","journal-title":"ACS Nano"},{"key":"4703_CR179","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005834","author":"C Mao","year":"2022","unstructured":"Mao C, Beiss V, Ho GW, Fields J, Steinmetz NF, Fiering S. In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005834.","journal-title":"J Immunother Cancer"},{"key":"4703_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.celbio.2025.100011","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yang M, Zhang B-Y, Zhao G, Zhou S-K, Lu Z-D, et al. Leveraging T cell-specific fusogenicity of HIV for in vivo mRNA delivery to produce human CAR-T cells. Cell Biomater. 2025. https:\/\/doi.org\/10.1016\/j.celbio.2025.100011.","journal-title":"Cell Biomater"},{"key":"4703_CR181","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12672-023-00680-9","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Lu B, Deng Z, Xing F, Hsu W. Virus-like particle-based delivery of Cas9\/guide RNA ribonucleoprotein efficiently edits the brachyury gene and inhibits chordoma growth in vivo. Discov Oncol. 2023;14:70.","journal-title":"Discov Oncol"},{"key":"4703_CR182","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41417-023-00597-z","volume":"30","author":"SE Ahmadi","year":"2023","unstructured":"Ahmadi SE, Soleymani M, Shahriyary F, Amirzargar MR, Ofoghi M, Fattahi MD, Safa M. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR\/Cas-mediated cancer therapy. Cancer Gene Ther. 2023;30:936\u201354.","journal-title":"Cancer Gene Ther"},{"key":"4703_CR183","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/14712598.2022.2012148","volume":"22","author":"L Marrone","year":"2022","unstructured":"Marrone L, Marchi PM, Azzouz M. Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders. Expert Opin Biol Ther. 2022;22:1163\u201376.","journal-title":"Expert Opin Biol Ther"},{"key":"4703_CR184","doi-asserted-by":"publisher","first-page":"e00010","DOI":"10.1002\/ggn2.202500010","volume":"6","author":"F Liang","year":"2025","unstructured":"Liang F, Cui S, Yang J, He Z, Zhu L. Nanoplatform-Enabled Genetic Interventions for Central Nervous System Disorders: Advances in Delivery Strategies and Therapeutic Potential. Adv Genet (Hoboken). 2025;6:e00010.","journal-title":"Adv Genet (Hoboken)"},{"key":"4703_CR185","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1586\/14760584.3.2.119","volume":"3","author":"C Venters","year":"2004","unstructured":"Venters C, Graham W, Cassidy W. Recombivax-HB: perspectives past, present and future. Expert Rev Vaccines. 2004;3:119\u201329.","journal-title":"Expert Rev Vaccines"},{"key":"4703_CR186","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","volume":"336","author":"M-H Chang","year":"1997","unstructured":"Chang M-H, Chen C-J, Lai M-S, Hsu H-M, Wu T-C, Kong M-S, Liang D-C, Shau W-Y, Chen D-S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 1997;336:1855\u20139.","journal-title":"N Engl J Med"},{"key":"4703_CR187","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3390\/v15051109","volume":"15","author":"M Kheirvari","year":"2023","unstructured":"Kheirvari M, Liu H, Tumban E. Virus-like particle vaccines and platforms for vaccine development. Viruses. 2023;15:1109.","journal-title":"Viruses"},{"key":"4703_CR188","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1016\/j.vaccine.2015.05.066","volume":"33","author":"M Zahid","year":"2015","unstructured":"Zahid M, L\u00fcnsdorf H, Rinas U. Assessing stability and assembly of the hepatitis B surface antigen into virus-like particles during down-stream processing. Vaccine. 2015;33:3739\u201345.","journal-title":"Vaccine"},{"key":"4703_CR189","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2165\/00003495-200666090-00008","volume":"66","author":"MAA Siddiqui","year":"2006","unstructured":"Siddiqui MAA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil\u00ae). Drugs. 2006;66:1263\u201371.","journal-title":"Drugs"},{"key":"4703_CR190","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s00761-021-00932-9","volume":"27","author":"G Alakus","year":"2021","unstructured":"Alakus G, Malter W, Hartmann M, Alakus H, Bruns C. HPV vaccination and the risk of invasive cervical cancer. Onkologe. 2021;27:508\u201310.","journal-title":"Onkologe"},{"key":"4703_CR191","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","volume":"13","author":"M Lehtinen","year":"2012","unstructured":"Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagu\u00e9 X, et al. Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The lancet oncology. 2012;13:89\u201399.","journal-title":"The lancet oncology"},{"key":"4703_CR192","doi-asserted-by":"publisher","first-page":"TPS2100","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2100","volume":"42","author":"RT Merrell","year":"2024","unstructured":"Merrell RT, Wen PY, Forst DA, Schulte J, Odia Y, Bota DA, et al. Randomized phase IIb trial of a CMV vaccine immunotherapeutic candidate (VBI-1901) in recurrent glioblastomas. J Clin Oncol. 2024;42:TPS2100\u2013TPS2100.","journal-title":"J Clin Oncol"},{"key":"4703_CR193","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cellular & molecular immunology. 2024;21:1354\u201375.","journal-title":"Cellular & molecular immunology"},{"key":"4703_CR194","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1002\/eji.201142361","volume":"42","author":"SM Goldinger","year":"2012","unstructured":"Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann\u2010Haenni A, et al. Nano\u2010particle vaccination combined with TLR\u20107 and\u20109 ligands triggers memory and effector CD 8\u2009+\u2009T\u2010cell responses in melanoma patients. European journal of immunology. 2012;42:3049\u201361.","journal-title":"European journal of immunology"},{"key":"4703_CR195","doi-asserted-by":"publisher","first-page":"e1290036","DOI":"10.1080\/2162402X.2017.1290036","volume":"6","author":"AJ Grippin","year":"2017","unstructured":"Grippin AJ, Sayour EJ, Mitchell DA. Translational nanoparticle engineering for cancer vaccines. Oncoimmunology. 2017;6:e1290036.","journal-title":"Oncoimmunology"},{"key":"4703_CR196","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.omtm.2022.12.003","volume":"28","author":"S Besson","year":"2023","unstructured":"Besson S, Boucher E, Laurin D, Manches O, Aspord C, Hannani D, et al. Stimulation of the immune system by a tumor antigen-bearing adenovirus-inspired VLP allows control of melanoma growth. Mol Ther Methods Clin Dev. 2023;28:76\u201389.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4703_CR197","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433330","volume":"44","author":"AJ Rosenberg","year":"2024","unstructured":"Rosenberg AJ, Perez CA, Guo W, de Oliveira Novaes JM, da Silva Reis KFO, McGarrah PW, et al. Breaking ground in recurrent or metastatic head and neck squamous cell carcinoma: novel therapies beyond PD-L1 immunotherapy. Am Soc Clin Oncol Educ Book. 2024;44:e433330.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4703_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmt.2021.101110","volume":"24","author":"Q Guo","year":"2021","unstructured":"Guo Q, Wang C, Zhang Q, Cheng K, Shan W, Wang X, et al. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of HBc VLPs based cancer vaccine. Appl Mater Today. 2021;24:101110.","journal-title":"Appl Mater Today"},{"key":"4703_CR199","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1039\/D2TB02163C","volume":"11","author":"C Wang","year":"2023","unstructured":"Wang C, Xiao C, Chen Y, Li Y, Zhang Q, Shan W, et al. Sequential administration of virus-like particle-based nanomedicine to elicit enhanced tumor chemotherapy. J Mater Chem B. 2023;11:2674\u201383.","journal-title":"J Mater Chem B"},{"key":"4703_CR200","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.nano.2017.12.002","volume":"14","author":"W Shan","year":"2018","unstructured":"Shan W, Zhang D, Wu Y, Lv X, Hu B, Zhou X, et al. Modularized peptides modified HBc virus-like particles for encapsulation and tumor-targeted delivery of doxorubicin. Nanomedicine (Lond). 2018;14:725\u201334.","journal-title":"Nanomedicine (Lond)"},{"key":"4703_CR201","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202000077","volume":"15","author":"H Hu","year":"2020","unstructured":"Hu H, Steinmetz NF. Doxorubicin-loaded physalis mottle virus particles function as a pH\u2010responsive prodrug enabling cancer therapy. Biotechnol J. 2020;15:2000077.","journal-title":"Biotechnol J"},{"key":"4703_CR202","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201908743","volume":"30","author":"H Cai","year":"2020","unstructured":"Cai H, Shukla S, Steinmetz NF. The antitumor efficacy of CpG oligonucleotides is improved by encapsulation in plant virus-like particles. Adv Funct Mater. 2020;30:1908743.","journal-title":"Adv Funct Mater"},{"key":"4703_CR203","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nnano.2015.292","volume":"11","author":"P Lizotte","year":"2016","unstructured":"Lizotte P, Wen A, Sheen M, Fields J, Rojanasopondist P, Steinmetz N, et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat Nanotechnol. 2016;11:295\u2013303.","journal-title":"Nat Nanotechnol"},{"key":"4703_CR204","doi-asserted-by":"publisher","first-page":"e005834","DOI":"10.1136\/jitc-2022-005834","volume":"10","author":"C Mao","year":"2022","unstructured":"Mao C, Beiss V, Ho GW, Fields J, Steinmetz NF, Fiering S. In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade. J Immunother Cancer. 2022;10:e005834.","journal-title":"J Immunother Cancer"},{"key":"4703_CR205","doi-asserted-by":"publisher","first-page":"10407","DOI":"10.1021\/acsnano.3c01102","volume":"17","author":"H-H Pang","year":"2023","unstructured":"Pang H-H, Huang C-Y, Chen P-Y, Li N-S, Hsu Y-P, Wu J-K, et al. Bioengineered bacteriophage-like nanoparticles as RNAi therapeutics to enhance radiotherapy against glioblastomas. ACS nano. 2023;17:10407\u201322.","journal-title":"ACS nano"},{"key":"4703_CR206","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00680-9","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Lu B, Deng Z, Xing F, Hsu W. Virus-like particle-based delivery of Cas9\/guide RNA ribonucleoprotein efficiently edits the brachyury gene and inhibits chordoma growth in vivo. Discover Oncology. 2023;14:70.","journal-title":"Discover Oncology"},{"key":"4703_CR207","doi-asserted-by":"publisher","first-page":"10059","DOI":"10.1093\/nar\/gkad676","volume":"51","author":"J Haldrup","year":"2023","unstructured":"Haldrup J, Andersen S, Labial ARL, Wolff JH, Frandsen FP, Skov TW, et al. Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR\/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification. Nucleic Acids Research. 2023;51:10059\u201374.","journal-title":"Nucleic Acids Research"},{"key":"4703_CR208","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.trsl.2011.11.005","volume":"159","author":"SS Pinho","year":"2012","unstructured":"Pinho SS, Carvalho S, Cabral J, Reis CA, Gartner F. Canine tumors: a spontaneous animal model of human carcinogenesis. Transl Res. 2012;159:165\u201372.","journal-title":"Transl Res"},{"key":"4703_CR209","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrc2273","volume":"8","author":"M Paoloni","year":"2008","unstructured":"Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews Cancer. 2008;8:147\u201356.","journal-title":"Nature Reviews Cancer"},{"key":"4703_CR210","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/vetsci2030111","volume":"2","author":"CM Cannon","year":"2015","unstructured":"Cannon CM. Cats, cancer and comparative oncology. Veterinary sciences. 2015;2:111\u201326.","journal-title":"Veterinary sciences"},{"key":"4703_CR211","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer cell. 2020;37:471\u201384.","journal-title":"Cancer cell"},{"key":"4703_CR212","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41568-020-0297-3","volume":"20","author":"AK LeBlanc","year":"2020","unstructured":"LeBlanc AK, Mazcko CN. Improving human cancer therapy through the evaluation of pet dogs. Nat Rev Cancer. 2020;20:727\u201342.","journal-title":"Nat Rev Cancer"},{"key":"4703_CR213","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98\u2013106.","journal-title":"Am J Clin Oncol"},{"key":"4703_CR214","doi-asserted-by":"publisher","first-page":"e0157176","DOI":"10.1371\/journal.pone.0157176","volume":"11","author":"N Maekawa","year":"2016","unstructured":"Maekawa N, Konnai S, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Takagi S, Kagawa Y, Nakajima C, Suzuki Y. Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma. PLoS ONE. 2016;11:e0157176.","journal-title":"PLoS ONE"},{"key":"4703_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75533-4","volume":"10","author":"M Igase","year":"2020","unstructured":"Igase M, Nemoto Y, Itamoto K, Tani K, Nakaichi M, Sakurai M, et al. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. Sci Rep. 2020;10:18311.","journal-title":"Sci Rep"},{"key":"4703_CR216","doi-asserted-by":"publisher","first-page":"e0281143","DOI":"10.1371\/journal.pone.0281143","volume":"18","author":"N Maekawa","year":"2023","unstructured":"Maekawa N, Konnai S, Asano Y, Otsuka T, Aoki E, Takeuchi H, Kato Y, Kaneko MK, Yamada S, Kagawa Y. Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors. PLoS ONE. 2023;18:e0281143.","journal-title":"PLoS ONE"},{"key":"4703_CR217","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"4703_CR218","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2025.1674694","volume":"12","author":"M Rizzi","year":"2025","unstructured":"Rizzi M, D\u2019Annunzio G, Tugnoli C, Sarli G, Muscatello LV. The immune microenvironment in tumors: focus on canine and feline spontaneous neoplasms. Front Vet Sci. 2025;12:1674694.","journal-title":"Front Vet Sci"},{"key":"4703_CR219","doi-asserted-by":"publisher","DOI":"10.3390\/cells11162578","volume":"11","author":"C Nascimento","year":"2022","unstructured":"Nascimento C, Gameiro A, Correia J, Ferreira J, Ferreira F. The landscape of tumor-infiltrating immune cells in feline mammary carcinoma: pathological and clinical implications. Cells. 2022;11:2578.","journal-title":"Cells"},{"key":"4703_CR220","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"key":"4703_CR221","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22:1865\u201374.","journal-title":"Clin Cancer Res"},{"key":"4703_CR222","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373\u201384.","journal-title":"Nat Immunol"},{"key":"4703_CR223","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01100","volume":"11","author":"J Zepeda-Cervantes","year":"2020","unstructured":"Zepeda-Cervantes J, Ram\u00edrez-Jarqu\u00edn JO, Vaca L. Interaction between virus-like particles (VLPs) and pattern recognition receptors (PRRs) from dendritic cells (DCs): toward better engineering of VLPs. Front Immunol. 2020;11:1100.","journal-title":"Front Immunol"},{"key":"4703_CR224","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00316","volume":"5","author":"C Vaure","year":"2014","unstructured":"Vaure C, Liu Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front Immunol. 2014;5:316.","journal-title":"Front Immunol"},{"key":"4703_CR225","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.vetimm.2005.02.022","volume":"106","author":"G Ignacio","year":"2005","unstructured":"Ignacio G, Nordone S, Howard KE, Dean GA. Toll-like receptor expression in feline lymphoid tissues. Vet Immunol Immunopathol. 2005;106:229\u201337.","journal-title":"Vet Immunol Immunopathol"},{"key":"4703_CR226","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2005.11.010","volume":"24","author":"F Nimmerjahn","year":"2006","unstructured":"Nimmerjahn F, Ravetch JV. Fc\u03b3 receptors: old friends and new family members. Immunity. 2006;24:19\u201328.","journal-title":"Immunity"},{"key":"4703_CR227","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","volume":"113","author":"P Bruhns","year":"2009","unstructured":"Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fc\u03b3 receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113:3716\u201325.","journal-title":"Blood"},{"key":"4703_CR228","doi-asserted-by":"publisher","first-page":"841859","DOI":"10.3389\/fimmu.2022.841859","volume":"13","author":"R Hullsiek","year":"2022","unstructured":"Hullsiek R, Li Y, Snyder KM, Wang S, Di D, Borgatti A, Lee C, Moore PF, Zhu C, Fattori C. Examination of IgG Fc receptor CD16A and CD64 expression by canine leukocytes and their ADCC activity in engineered NK cells. Front Immunol. 2022;13:841859.","journal-title":"Front Immunol"},{"key":"4703_CR229","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.vetimm.2014.01.012","volume":"158","author":"CJ Strietzel","year":"2014","unstructured":"Strietzel CJ, Bergeron LM, Oliphant T, Mutchler VT, Choromanski LJ, Bainbridge G. In vitro functional characterization of feline IgGs. Vet Immunol Immunopathol. 2014;158:214\u201323.","journal-title":"Vet Immunol Immunopathol"},{"key":"4703_CR230","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1158\/1078-0432.CCR-15-2347","volume":"22","author":"AK LeBlanc","year":"2016","unstructured":"LeBlanc AK, Mazcko CN, Khanna C. Defining the value of a comparative approach to cancer drug development. Clin Cancer Res. 2016;22:2133\u20138.","journal-title":"Clin Cancer Res"},{"key":"4703_CR231","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.cvsm.2007.08.003","volume":"37","author":"MC Paoloni","year":"2007","unstructured":"Paoloni MC, Khanna C. Comparative oncology today. Veterinary Clin North America: Small Anim Pract. 2007;37:1023\u201332.","journal-title":"Veterinary Clin North America: Small Anim Pract"},{"key":"4703_CR232","first-page":"1209","volume":"18","author":"AK LeBlanc","year":"2016","unstructured":"LeBlanc AK, Mazcko C, Brown DE, Koehler JW, Miller AD, Miller CR, Bentley RT, Packer RA, Breen M, Boudreau CE. Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients. Neurooncology. 2016;18:1209\u201318.","journal-title":"Neurooncology"},{"key":"4703_CR233","doi-asserted-by":"publisher","first-page":"e1000161","DOI":"10.1371\/journal.pmed.1000161","volume":"6","author":"I Gordon","year":"2009","unstructured":"Gordon I, Paoloni M, Mazcko C, Khanna C. The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med. 2009;6:e1000161.","journal-title":"PLoS Med"},{"key":"4703_CR234","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1158\/1078-0432.CCR-09-0719","volume":"15","author":"C Khanna","year":"2009","unstructured":"Khanna C, London C, Vail D, Mazcko C, Hirschfeld S. Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clin Cancer Res. 2009;15:5671\u20137.","journal-title":"Clin Cancer Res"},{"key":"4703_CR235","doi-asserted-by":"publisher","first-page":"1504124","DOI":"10.3389\/fimmu.2024.1504124","volume":"15","author":"W Ning","year":"2025","unstructured":"Ning W, Yan S, Song Y, Xu H, Zhang J, Wang X. Virus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response. Front Immunol. 2025;15:1504124.","journal-title":"Front Immunol"},{"key":"4703_CR236","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00829","volume":"8","author":"WK Decker","year":"2017","unstructured":"Decker WK, da Silva RF, Sanabria MH, Angelo LS, Guimar\u00e3es F, Burt BM, et al. Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models. Front Immunol. 2017;8:829.","journal-title":"Front Immunol"},{"key":"4703_CR237","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/14760584.2022.2029415","volume":"21","author":"H McFall-Boegeman","year":"2022","unstructured":"McFall-Boegeman H, Huang X. Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines. Expert Rev Vaccines. 2022;21:453\u201369.","journal-title":"Expert Rev Vaccines"},{"key":"4703_CR238","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.immuni.2024.03.014","volume":"57","author":"SL Carroll","year":"2024","unstructured":"Carroll SL, Pasare C, Barton GM. Control of adaptive immunity by pattern recognition receptors. Immunity. 2024;57:632\u201348.","journal-title":"Immunity"},{"key":"4703_CR239","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.3390\/cells12182241","volume":"12","author":"G Valdivia","year":"2023","unstructured":"Valdivia G, Alonso-Miguel D, Perez-Alenza MD, Zimmermann ABE, Schaafsma E, Kolling IVFW, Barreno L, Alonso-Diez A, Beiss V. Affonso de Oliveira JF: Neoadjuvant intratumoral immunotherapy with cowpea mosaic virus induces local and systemic antitumor efficacy in canine mammary cancer patients. Cells. 2023;12:2241.","journal-title":"Cells"},{"key":"4703_CR240","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1566394","volume":"16","author":"A Singh","year":"2025","unstructured":"Singh A, Affonso de Oliveira JF, Schrader J, Kishore D, Chandrasekar SV, Fiering S, et al. Immunomodulatory effects of intratumoral cowpea mosaic virus and calreticulin nanoparticles in canine tumors: early results. Front Immunol. 2025;16:1566394.","journal-title":"Front Immunol"},{"key":"4703_CR241","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1021\/acs.molpharmaceut.5c00100","volume":"22","author":"P Delgado-Bonet","year":"2025","unstructured":"Delgado-Bonet P, Arias-Pulido H, del Castillo Magan N, Emilia Zimmermann AB, Schaafsma E, Vom Berg J, et al. Pilot Study of Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles: Safety in Refractory Canine Oral Tumors. Mol Pharm. 2025;22:2671\u201383.","journal-title":"Mol Pharm"},{"key":"4703_CR242","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00129-19","volume":"93","author":"C Wang","year":"2019","unstructured":"Wang C, Beiss V, Steinmetz NF. Cowpea mosaic virus nanoparticles and empty virus-like particles show distinct but overlapping immunostimulatory properties. J Virol. 2019;93:10.1128\/jvi. 00129\u2009\u2212\u200900119.","journal-title":"J Virol"},{"key":"4703_CR243","doi-asserted-by":"publisher","first-page":"e002927","DOI":"10.1136\/jitc-2021-002927","volume":"10","author":"MO Mohsen","year":"2022","unstructured":"Mohsen MO, Speiser DE, Michaux J, Pak H, Stevenson BJ, Vogel M, Inchakalody VP, de Brot S, Dermime S, Coukos G. Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma. J Immunother Cancer. 2022;10:e002927.","journal-title":"J Immunother Cancer"},{"key":"4703_CR244","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1158\/2159-8290.CD-18-0044","volume":"8","author":"B Olson","year":"2018","unstructured":"Olson B, Li Y, Lin Y, Liu ET, Patnai A. Mouse models for cancer immunotherapy research. Cancer Discov. 2018;8:1358.","journal-title":"Cancer Discov"},{"key":"4703_CR245","first-page":"114","volume":"6","author":"IW Mak","year":"2014","unstructured":"Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J translational Res. 2014;6:114.","journal-title":"Am J translational Res"},{"key":"4703_CR246","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0200-7","volume":"4","author":"JS Park","year":"2016","unstructured":"Park JS, Withers SS, Modiano JF, Kent MS, Chen M, Luna JI, et al. Canine cancer immunotherapy studies: linking mouse and human. Journal for immunotherapy of cancer. 2016;4:97.","journal-title":"Journal for immunotherapy of cancer"},{"key":"4703_CR247","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.tvjl.2018.08.008","volume":"240","author":"O Garden","year":"2018","unstructured":"Garden O, Volk S, Mason N, Perry J. Companion animals in comparative oncology: one medicine in action. The Veterinary Journal. 2018;240:6\u201313.","journal-title":"The Veterinary Journal"},{"key":"4703_CR248","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1146\/annurev-animal-111523-101930","volume":"14","author":"JM Fenger","year":"2026","unstructured":"Fenger JM, London CA. Dogs as a model for cancer: an update. Annual Review of Animal Biosciences. 2026;14:341\u201374.","journal-title":"Annual Review of Animal Biosciences"},{"key":"4703_CR249","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/ilar.51.3.214","volume":"51","author":"IK Gordon","year":"2010","unstructured":"Gordon IK, Khanna C. Modeling opportunities in comparative oncology for drug development. ILAR journal. 2010;51:214\u201320.","journal-title":"ILAR journal"},{"key":"4703_CR250","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.tvjl.2015.10.008","volume":"207","author":"D Regan","year":"2016","unstructured":"Regan D, Guth A, Coy J, Dow S. Cancer immunotherapy in veterinary medicine: current options and new developments. The Veterinary Journal. 2016;207:20\u20138.","journal-title":"The Veterinary Journal"},{"key":"4703_CR251","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110404","volume":"10","author":"D S\u00e1nchez","year":"2018","unstructured":"S\u00e1nchez D, Cesarman-Maus G, Amador-Molina A, Lizano M. Oncolytic viruses for canine cancer treatment. Cancers. 2018;10:404.","journal-title":"Cancers"},{"key":"4703_CR252","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2024.110816","volume":"275","author":"HP Lang","year":"2024","unstructured":"Lang HP, Osum KC, Friedenberg SG. A review of CD4\u2009+\u2009T cell differentiation and diversity in dogs. Veterinary immunology and immunopathology. 2024;275:110816.","journal-title":"Veterinary immunology and immunopathology"},{"key":"4703_CR253","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s13071-016-1798-5","volume":"9","author":"MJ Day","year":"2016","unstructured":"Day MJ. Cats are not small dogs: is there an immunological explanation for why cats are less affected by arthropod-borne disease than dogs? Parasites vectors. 2016;9:507.","journal-title":"Parasites vectors"},{"key":"4703_CR254","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.vetimm.2013.10.018","volume":"157","author":"LM Bergeron","year":"2014","unstructured":"Bergeron LM, McCandless EE, Dunham S, Dunkle B, Zhu Y, Shelly J, et al. Comparative functional characterization of canine IgG subclasses. Veterinary immunology and immunopathology. 2014;157:31\u201341.","journal-title":"Veterinary immunology and immunopathology"},{"key":"4703_CR255","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41577-020-00410-0","volume":"20","author":"S Bournazos","year":"2020","unstructured":"Bournazos S, Gupta A, Ravetch JV. The role of IgG Fc receptors in antibody-dependent enhancement. Nature Reviews Immunology. 2020;20:633\u201343.","journal-title":"Nature Reviews Immunology"},{"key":"4703_CR256","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1438004","volume":"15","author":"R Ramarapu","year":"2024","unstructured":"Ramarapu R, Wulcan JM, Chang H, Moore PF, Vernau W, Keller SM. Single cell RNA-sequencing of feline peripheral immune cells with V (D) J repertoire and cross species analysis of T lymphocytes. Frontiers in Immunology. 2024;15:1438004.","journal-title":"Frontiers in Immunology"},{"key":"4703_CR257","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48425-5","volume":"9","author":"YJ Tan","year":"2019","unstructured":"Tan YJ, Crowley RJ, Ioannidis JP. An empirical assessment of research practices across 163 clinical trials of tumor-bearing companion dogs. Scientific Reports. 2019;9:11877.","journal-title":"Scientific Reports"},{"key":"4703_CR258","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1146\/annurev-biodatasci-102423-111936","volume":"7","author":"JA Cahill","year":"2024","unstructured":"Cahill JA, Smith LA, Gottipati S, Torabi TS, Graim K. Bringing the genomic revolution to comparative oncology: human and dog cancers. Annual review of biomedical data science. 2024;7:107\u201329.","journal-title":"Annual review of biomedical data science"},{"key":"4703_CR259","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s12276-023-00977-3","volume":"55","author":"JH Oh","year":"2023","unstructured":"Oh JH, Cho J-Y. Comparative oncology: overcoming human cancer through companion animal studies. Experimental & Molecular Medicine. 2023;55:725\u201334.","journal-title":"Experimental & Molecular Medicine"},{"key":"4703_CR260","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1054231","volume":"12","author":"Y Cai","year":"2023","unstructured":"Cai Y, Chen R, Gao S, Li W, Liu Y, Su G, et al. Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy. Frontiers in oncology. 2023;12:1054231.","journal-title":"Frontiers in oncology"},{"key":"4703_CR261","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1021\/acs.bioconjchem.2c00030","volume":"33","author":"A Olshefsky","year":"2022","unstructured":"Olshefsky A, Richardson C, Pun SH, King NP. Engineering self-assembling protein nanoparticles for therapeutic delivery. Bioconjug Chem. 2022;33:2018\u201334.","journal-title":"Bioconjug Chem"},{"key":"4703_CR262","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1186\/s12964-024-01884-4","volume":"22","author":"H Xu","year":"2024","unstructured":"Xu H, Wen J, Yang J, Zhou S, Li Y, Xu K, Li W, Li S. Tumor-microenvironment-on-a-chip: the construction and application. Cell Communication Signal. 2024;22:515.","journal-title":"Cell Communication Signal"},{"key":"4703_CR263","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.drudis.2017.03.011","volume":"22","author":"YS Zhang","year":"2017","unstructured":"Zhang YS, Zhang Y-N, Zhang W. Cancer-on-a-chip systems at the frontier of nanomedicine. Drug Discovery Today. 2017;22:1392\u20139.","journal-title":"Drug Discovery Today"},{"key":"4703_CR264","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3390\/v12050488","volume":"12","author":"JC Caldeira","year":"2020","unstructured":"Caldeira JC, Perrine M, Pericle F, Cavallo F. Virus-like particles as an immunogenic platform for cancer vaccines. Viruses. 2020;12:488.","journal-title":"Viruses"},{"key":"4703_CR265","doi-asserted-by":"publisher","first-page":"1106767","DOI":"10.3389\/fbioe.2022.1106767","volume":"10","author":"KR Kim","year":"2023","unstructured":"Kim KR, Lee AS, Kim SM, Heo HR, Kim CS. Virus-like nanoparticles as a theranostic platform for cancer. Front Bioeng Biotechnol. 2023;10:1106767.","journal-title":"Front Bioeng Biotechnol"},{"key":"4703_CR266","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41423-022-00897-8","volume":"19","author":"MO Mohsen","year":"2022","unstructured":"Mohsen MO, Bachmann MF. Virus-like particle vaccinology, from bench to bedside. Cell Mol Immunol. 2022;19:993\u20131011.","journal-title":"Cell Mol Immunol"},{"key":"4703_CR267","doi-asserted-by":"publisher","first-page":"20140231","DOI":"10.1098\/rstb.2014.0231","volume":"370","author":"JD Schiffman","year":"2015","unstructured":"Schiffman JD, Breen M. Comparative oncology: what dogs and other species can teach us about humans with cancer. Philosophical Trans Royal Soc B: Biol Sci. 2015;370:20140231.","journal-title":"Philosophical Trans Royal Soc B: Biol Sci"},{"key":"4703_CR268","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/s41565-024-01753-8","volume":"19","author":"L Rao","year":"2024","unstructured":"Rao L, Yuan Y, Shen X, Yu G, Chen X. Designing nanotheranostics with machine learning. Nat Nanotechnol. 2024;19:1769\u201381.","journal-title":"Nat Nanotechnol"},{"key":"4703_CR269","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"4703_CR270","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.975054","volume":"9","author":"S De S\u00e1 Magalh\u00e3es","year":"2022","unstructured":"De S\u00e1 Magalh\u00e3es S, De Santis E, Hussein-Gore S, Colomb-Delsuc M, Keshavarz-Moore E. Quality assessment of virus-like particle: A new transmission electron microscopy approach. Front Mol Biosci. 2022;9:975054.","journal-title":"Front Mol Biosci"},{"key":"4703_CR271","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1123805","volume":"14","author":"R Gupta","year":"2023","unstructured":"Gupta R, Arora K, Roy SS, Joseph A, Rastogi R, Arora NM, et al. Platforms, advances, and technical challenges in virus-like particles-based vaccines. Front Immunol. 2023;14:1123805.","journal-title":"Front Immunol"},{"key":"4703_CR272","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms14040858","volume":"14","author":"J Zhang","year":"2026","unstructured":"Zhang J, Chen C. Downstream Purification Strategies for Virus-like Particles: A Systematic Review of Structure Preservation, Impurity Control, and Viral Safety. Microorganisms. 2026;14:858.","journal-title":"Microorganisms"},{"key":"4703_CR273","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0243-4","volume":"5","author":"S Gnjatic","year":"2017","unstructured":"Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017;5:44.","journal-title":"J Immunother Cancer"},{"key":"4703_CR274","doi-asserted-by":"publisher","first-page":"35385","DOI":"10.1021\/acsnano.5c06278","volume":"19","author":"S Zhou","year":"2025","unstructured":"Zhou S, Wang C, Ning Y, Wang Y, Xin F, Ren L, et al. Virus-Like Particle-Based Personalized Neoantigen Nano-Vaccine for Tumor Immunotherapy and Recurrence Prevention. ACS Nano. 2025;19:35385\u2013400.","journal-title":"ACS Nano"},{"key":"4703_CR275","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04843-8","volume":"22","author":"A Barajas","year":"2024","unstructured":"Barajas A, Amengual-Rigo P, Pons-Gr\u00edfols A, Ortiz R, Gracia Carmona O, Urrea V, et al. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice. J Transl Med. 2024;22:14.","journal-title":"J Transl Med"},{"key":"4703_CR276","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612963","volume":"24","author":"F Ruzzi","year":"2023","unstructured":"Ruzzi F, Semprini MS, Scalambra L, Palladini A, Angelicola S, Cappello C, et al. Virus-like particle (VLP) vaccines for cancer immunotherapy. Int J Mol Sci. 2023;24:12963.","journal-title":"Int J Mol Sci"},{"key":"4703_CR277","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrc.2016.154","volume":"17","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Johnson IIIBA, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nature Reviews Cancer. 2017;17:209\u201322.","journal-title":"Nature Reviews Cancer"},{"key":"4703_CR278","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41587-021-01038-8","volume":"40","author":"C Chong","year":"2022","unstructured":"Chong C, Coukos G, Bassani-Sternberg M. Identification of tumor antigens with immunopeptidomics. Nature biotechnology. 2022;40:175\u201388.","journal-title":"Nature biotechnology"},{"key":"4703_CR279","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nature Reviews Immunology. 2024;24:399\u2013416.","journal-title":"Nature Reviews Immunology"},{"key":"4703_CR280","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1093\/annonc\/mdy398","volume":"29","author":"M Smoragiewicz","year":"2018","unstructured":"Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, et al. Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on methodology for the development of innovative cancer therapies. Annals of Oncology. 2018;29:2175\u201382.","journal-title":"Annals of Oncology"},{"key":"4703_CR281","doi-asserted-by":"publisher","first-page":"26195","DOI":"10.1021\/jacs.5c02774","volume":"147","author":"C Zhao","year":"2025","unstructured":"Zhao C, Pan Y, Cao L, Tang Y, Chen X, Zhao X, et al. Metal-phenolic outer membrane vesicles for cancer radioimmunotherapy. Journal of the American Chemical Society. 2025;147:26195\u2013207.","journal-title":"Journal of the American Chemical Society"},{"key":"4703_CR282","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201901989","volume":"32","author":"O Adir","year":"2020","unstructured":"Adir O, Poley M, Chen G, Froim S, Krinsky N, Shklover J, et al. Integrating artificial intelligence and nanotechnology for precision cancer medicine. Advanced materials. 2020;32:1901989.","journal-title":"Advanced materials"},{"key":"4703_CR283","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1021\/accountsmr.4c00362","volume":"6","author":"X Lin","year":"2025","unstructured":"Lin X, Yue L, Cheng K, Rao L. Engineering cellular vesicles for immunotherapy. Accounts of Materials Research. 2025;6:327\u201339.","journal-title":"Accounts of Materials Research"},{"key":"4703_CR284","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2022.1007784","volume":"4","author":"EA Stahlberg","year":"2022","unstructured":"Stahlberg EA, Abdel-Rahman M, Aguilar B, Asadpoure A, Beckman RA, Borkon LL, et al. Exploring approaches for predictive cancer patient digital twins: opportunities for collaboration and innovation. Frontiers in Digital Health. 2022;4:1007784.","journal-title":"Frontiers in Digital Health"},{"key":"4703_CR285","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41746-024-01188-4","volume":"7","author":"H Wang","year":"2024","unstructured":"Wang H, Arulraj T, Ippolito A, Popel AS. From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling. NPJ Digit Med. 2024;7:189.","journal-title":"NPJ Digit Med"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04703-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04703-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04703-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:04:11Z","timestamp":1789394651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04703-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":285,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4703"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04703-9","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final version of the manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"867"}}